HBV/HDV-ACT CONNECT SLIDES
SATURDAY, MARCH 25, 2023
Session I: HBV
HBV Overview of the Last 3 Years For Drug Development: Phase 2 Trials
Ira M. Jacobson, MD
Is There a Real Difference between ETV and TDF/TAF in relapse and HCC?
W. Ray Kim, MD
Emerging Therapies in the Next 3 Years (Pre-clinical Phase 1)
Jorg Petersen, MD
Does the New Data on HBV DNA Integration and HBsAg Production Effect the Design and Definition of Treatment Endpoints of Phase II and Phase III Studies?
Ju-Tao Guo, MD
What Are the Most Promising Immunomodulatory Therapies for
Adam J. Gehring, PhD
How Do We Fit FNA and Liver Biopsy into HBV Drug Development and Design? Should All Studies Have FNA Subset and Examine Intrahepatic Immune Activity? CccDNA? Integrants?
Emerging Concepts and Data CPAMS Third and Fourth Generation
Man-Fung Yuen, MBBS, MD, PhD, DSc
SUNDAY, MARCH 26, 2023
Session II: HDV
HDV Update: Review of the Last 3 Years
Robert Gish, MD
What Is the Current Role of Interferon Therapy for HDV?
Christopher Koh, MD, MHSc, FACP, FAASLD
What Other Therapies Are Being Developed for HDV Infection? NAPS, Lambda, and Lonafarnib
Heiner Wedemeyer, MD